Format

Send to

Choose Destination
Front Oncol. 2014 Jul 21;4:174. doi: 10.3389/fonc.2014.00174. eCollection 2014.

A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer.

Author information

1
Department of Oncology, Segal Cancer Center, Sir Mortimer B. Davis Jewish General Hospital , Montreal, QC , Canada.
2
Division of Pulmonary Diseases, Department of Oncology, Peter Brojde Cancer Center , Montreal, QC , Canada.

Abstract

The identification of oncogenic driver mutations in non-small cell lung cancer (NSCLC) has led to a paradigm shift and the development of specific molecular treatments. Tumors harboring a rearranged EML4-ALK fusion oncogene are highly sensitive to therapy with ALK-targeted inhibitors. Crizotinib is the first approved treatment for advanced lung tumors containing this genetic abnormality. In this mini review, we discuss the existing data on crizotinib as well as ongoing trials involving this medication. A brief overview of the known resistance mechanisms to crizotinib will also be presented followed by a summary of the ongoing trials involving next-generation ALK-inhibitors or other targeted therapies in patients with ALK+ NSCLC.

KEYWORDS:

ALK-inhibitors; anaplastic lymphoma kinase; clinical trials as topic; crizotinib; driver mutations; non-small cell lung cancer

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center